Apixaban

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Apixaban and local guidelines before prescribing.

Direct factor Xa inhibitor (DOAC)

Mechanism

Direct factor Xa inhibitor.

Uses

Stroke prevention in non-valvular AF, treatment and prevention of VTE.

Dosing

4 more dose entries from the chapters

Side effects

Bleeding, anaemia, nausea; rarely hepatic injury.

Interactions

Strong CYP3A4 and P-gp inhibitors or inducers alter levels; avoid with other anticoagulants and caution with antiplatelets.

Contraindications and cautions

Active bleeding, prosthetic valve, antiphospholipid syndrome, severe liver disease

Monitoring

Renal function, Hb, weight

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Reduce dose with criteria in AF; avoid if CrCl below 15

Overdose and reversal

Andexanet alfa or prothrombin complex concentrate for life-threatening bleeding

Special advice

Dose reduce by age, weight and renal function criteria; andexanet alfa is the reversal agent; avoid in mechanical valves and antiphospholipid syndrome.

More from the textbook: uses, cautions and other points
Where it is discussed in the book